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Abstract
Background: Chronic hepatitis B virus (HBV) infection is an important cause of hepatocellular
carcinoma (HCC) worldwide. The pre-S1 and -S2 mutant large HBV surface antigen (LHBS), in
which the pre-S1 and -S2 regions of the LHBS gene are partially deleted, are highly associated with
HBV-related HCC.
Methods: The pre-S region of the LHBS gene in two hundred and one HBV-positive serum
samples was PCR-amplified and sequenced. A pre-S oligonucleotide gene chip was developed to
efficiently detect pre-S deletions in chronic HBV carriers. Twenty serum samples from chronic
HBV carriers were analyzed using the chip.
Results: The pre-S deletion rates were relatively low (7%) in the sera of patients with acute HBV
infection. They gradually increased in periods of persistent HBV infection: pre-S mutation rates
were 37% in chronic HBV carriers, and as high as 60% in HCC patients. The Pre-S Gene Chip offers
a highly sensitive and specific method for pre-S deletion detection and is less expensive and more
efficient (turnaround time 3 days) than DNA sequencing analysis.
Conclusion: The pre-S1/2 mutants may emerge during the long-term persistence of the HBV
genome in carriers and facilitate HCC development. Combined detection of pre-S mutations, other
markers of HBV replication, and viral titers, offers a reliable predictive method for HCC risks in
chronic HBV carriers.
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Background
Chronic hepatitis B virus infection is a major cause of
HCC worldwide and its most important cause in Asia [1-
6]. HBV infection occurs primarily through blood or body
fluid transmission. HBV-related HCC often occurs at the
age of 40 or older, suggesting that HBV may persist in car-
riers for decades before HCC actually develops [6,7].
Long-term monitoring of chronic HBV carriers is impor-
tant to help prevent HCC. Furthermore, implementing
cancer therapies at early disease stages is beneficial. The
HBV markers commonly used to monitor the viral status
in chronic HBV carriers are viral DNA titers, HBV surface
and core antigens, and hepatitis B envelope (HBe) antigen
[7,8]. Combined detection of these markers reveals the
status of virus replication as well as the number of virus
particles in host hepatocytes. Active HBV viral replication
and high virus titers are associated with the severity of
HBV-induced liver inflammation, fibrosis, cirrhosis, and
HCC [9,10].
In the late 1990s, two major types of pre-S deletion
mutant LHBS were identified and highly associated with
HCC [11,12]. LHBS is expressed primarily at the late stage
of chronic HBV infection, after the viral genome has inte-
grated into the host chromosome [13-16]. Pre-S mutant
LHBS was first isolated from ground-glass hepatocytes
(GGH), the histological hallmarks of the late stages of
chronic HBV infection, and is often seen in the liver sec-
tions of HCC patients [17]. Pre-S mutant LHBS is highly
associated with advanced liver diseases, including cirrho-
sis and HCC, which suggests that it contributes to hepato-
cellular carcinogenesis [18-26]. In the two types of pre-S
mutant LHBS, pre-S1 and pre-S2 mutant LHBS, the pre-S1
and -S2 regions are, respectively, partially deleted (Fig. 1)
[11,12]. They accumulate in endoplasmic reticulum (ER)
and induce strong ER stress [27]. Through an ER stress-
mediated pathway, they cause oxidative stress and DNA
damage [28]. Through an ER stress-independent pathway,
however, pre-S2 mutant LHBS contributes to the increased
proliferation of hepatocytes [29]. Pre-S2 mutant LHBS also
interacts with c-Jun activation domain-binding protein 1
(JAB1) and induces p27Kip1 degradation and cell-cycle
progression [30]. Through an unknown mechanism, pre-
S2 mutant LHBS also induces significant cyclin A expres-
sion [29]. Based on the findings of these previous studies,
pre-S mutant LHBS, especially the pre-S2 type, is believed
to be crucial in HBV-associated hepatocellular carcinogen-
esis.
After pre-S mutant LHBS was discovered, various geo-
graphically diverse studies [18-26] screening for pre-S
mutations invariably reported that they were prevalent in
chronic HBV carriers. In addition, pre-S mutant LHBS,
especially the pre-S2 type, is highly correlated with the
severity of HBV-related liver diseases, including HCC [20-
23,25]. Therefore, it is important to screen for pre-S dele-
tion mutations in chronic HBV carriers. This type of
screening should be done in combination with the detec-
tion of other HBV markers, such as viral titers and HBe
antigen (Ag), to estimate an HBV carrier's relative risk for
HCC.
Identifying pre-S mutations in chronic HBV carriers usu-
ally requires multiple experimental procedures, because
most pre-S mutants co-exist with wild-type LHBS in blood
and hepatocytes; this is probably due to the emergence of
the pre-S mutant from the wild-type form. One individual
carrier often simultaneously presents multiple pre-S
mutant forms that need to be singly cloned and then
sequenced. This is both time-consuming and expensive,
which makes it difficult to screen large populations of
chronic HBV carriers. We developed a convenient and
cost-effective oligonucleotide array system for screening
pre-S deletions in the LHBS gene. Using this system, we
omitted traditional DNA sequencing and shortened the
detection procedure from about 7 days to no longer than
3 working days.
Materials and methods
Reagents and participants
The pre-S region of the LHBS gene in two hundred and
one HBV-positive serum samples, collected at the
National Cheng Kung University Hospital from 2000
Representatives of the wild-type, pre-S1, and pre-S2 mutant  LHBS gene Figure 1
Representatives of the wild-type, pre-S1, and pre-S2 
mutant LHBS gene. The shaded boxes are the regions 
deleted in the pre-S1 and pre-S2 mutant LHBS. The numbers 
on the bottom of the gene indicate the pre-S1, S2, and S 
regions of the LHBS gene in nucleotide order. Nucleotide 1 is 
the start of the circular genome and the numbers go clock-
wise. The last nt number is 3221. Here only the S gene, which 
spans the start of the genome, is shown. The arrow at the 
top of the diagram indicates the start (nt 1) of the HBV 
genome.
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through 2002, was PCR-amplified and sequenced [31]. To
develop the Pre-S Gene Chip system, 20 HBV-DNA-posi-
tive serum samples were obtained from Kung-Chia
Young, PhD, at National Cheng Kung University. The pre-
S region of the LHBS gene was PCR-amplified and
sequenced [31]. The DNA sequences were used to design
oligonucleotide probes on the Pre-S Gene Chip. To test
the efficacy of the chip, another 20 serum samples from
chronic HBV carriers were obtained from the Center for
Disease Control, Taipei, Taiwan, and analyzed using the
chip. A DNA extraction kit (QIAamp MinElute Virus Spin
kit; Qiagen Inc., Valencia, CA) was used to extract the virus
DNA in serum. Most of the common chemicals used for
chip hybridization were purchased from Sigma-Aldrich
Co., St Louis, MO.
The Pre-S Gene Chip
The oligonucleotide DNA probe (20 M) was prepared in
DNA tracking dye (5 mM Tris-HCl, 0.5 mM Na2EDTA,
0.75 mg/mL bromophenol blue, 15% glycerol [pH 7.5]).
The 42 DNA probes spanning the pre-S region (532 nucle-
otides (nt)) of the LHBS gene were spotted on positively-
charged nylon membrane, using an arrayer (Ezspot
Robotic Arrayer; EZlife Technology, Inc., Taipei, Taiwan)
with a solid pin 400 m in diameter. The probes ranged
from 25 to 30 nt long, and some were linked with 15 to
17 thymidines at the 5' ends. Redundant probes were
designed to target the genetically polymorphic regions in
the gene (Fig. 2). After the probes had been spotted, the
DNA on the membrane was ultravioletly (UV) cross-
linked (Stratalinker UV Crosslinker; Stratagene, La Jolla,
CA) to the nylon membrane.
Polymerase chain reaction
The pre-S LHBS gene was PCR amplified by using the
primers 1F (digoxigenin labeled at the 5' end) and 1R
(Table 1). In cases where no visible DNA products were
seen using agarose gel electrophoresis because of low viral
titers in the serum samples, nested PCR using the primers
1F and 2R was then done (Fig. 3). For E. coli colony PCR,
the M13 Forward (digoxigenin labeled at the 5' end) and
M13 Reverse primers (Invitrogen, Inc., Carlsbad, CA) were
used. The PCR mix contained 10 ng of template DNA, 0.2
M of each primer, 200 M of each dNTP, 0.5 units of
SuperTherm Fold DNA polymerase (JMR Holdings, Inc.,
Commerce Township, MI) with 1.5 mM of MgCl2, 25 mM
of N- [Tris (hydroxymethyl) methyl]-3-aminopropanesul-
fonic acid (TAPS [pH 9.3]), 50 mM of KCl, 2 mM of
MgCl2, 1 mM of -mercaptoethanol, and 0.25 g/L of
The Pre-S Gene Chip Figure 2
The Pre-S Gene Chip. The chip (7 mm (H) × 10 mm (W)) contains 42 oligonucleotide probes spanning the pre-S regions. 
The target region of each probe is indicated in the order of the nucleotides below the chip. The probes with extension num-
bers (e.g., 8-1, 8-2,... 8-6) are the redundant probes that target the same regions as the primary probes (e.g., 8) do.
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activated calf thymus DNA. Agarose gel electrophoresis
was used to examined the PCR products.
TA cloning
In cases where multiple pre-S PCR products were revealed,
E. coli TA cloning was done. Three microliters of PCR
product was ligated with 50 ng of TA cloning vector (pCR
2.1; Invitrogen) at 14°C overnight. The next day, the liga-
tion product was transformed into an E. coli DH5 strain.
The pre-S insert-DNA was then examined using colony
PCR. For the DNA sequencing analysis, the colony PCR
products were purified using a kit (PCR Clean-Up Kit;
Roche Applied Sciences, Indianapolis, IN) and sent to our
university's DNA Sequencing Facility for analysis.
Pre-S Gene Chip analysis
The pre-S chip was placed in a 24-well culture plate,
soaked in 0.2× standard sodium citrate (SSC: 150 mM
NaCl, 15 mM NaH2(C3H5O(COO)3 [pH 7.0]), and then
rinsed twice with the same solution. For pre-hybridiza-
tion, the chip was then gently shaken in microarray
hybridization buffer (5× SSC, 1% blocking reagent
(Roche), 0.1% N-lauroylsarcosine, 0.02% SDS) at room
temperature for 2 h. The chip was then hybridized with 10
L of heat-denatured PCR product in 300 L of hybridiza-
tion buffer at 50°C for 90 min while being gently shaken
(60 rpm). After it had been hybridized, the chip was
washed four times with 0.1× SSC and then incubated in
1× blocking reagent at room temperature for 1 h. The dig-
oxigenin that had hybridized to the DNA probes on the
chip was then recognized by incubating the chip with
0.375 units of anti-digoxigenin-alkaline phosphatase Fab
fragments (Roche) for 1 h. After it had been incubated, the
chip was washed 3 times with MAB washing buffer (MAB:
0.1 M maleic acid, 0.15 M NaCl, 0.1% Tween 20 [pH 7.5])
for 15 min each. To detect digoxigenin signals, the chip
was first soaked in a detection buffer (0.1 M Tris-HCl, 0.1
M NaCl [pH 9.5]) for 5 min and then incubated with two
alkaline phosphatase substrates: nitro blue tetrazolium
chloride (NBT, 0.375 mg/mL) and 5-bromo-4-chloro-3-
indolyl phosphate (BCIP, 0.188 mg/mL) at 37°C for 20
min in the dark. Finally, the chip was washed 3 times with
ddH2O and air-dried. Chip images were scanned using an
Epson Perfection 1250 scanner [32].
Table 1: The PCR primers used in this study.
Primer Sequence Comment
Primer-1F 5'-GCGGGTCACCATATTCTTGGG-3' HBV genome nt 2818 to nt 2837
Primer-1R 5'-GAGTCTAGACTCTGCGGTAT-3' HBV genome nt 236 to nt 255
Primer-2R 5'-TAACACGAGCAGGGGTCCTA-3' HBV genome nt 180 to nt 199
M13 Forward primer 5'-GTAAAACGACGGCCAGT-3'
M13 Reverse primer 5'-AACAGCTATGACCATG-3'
nt, nucleotide
Working scheme of Pre-S Gene Chip analysis Figure 3
Working scheme of Pre-S Gene Chip analysis. The 
virus DNA is extracted from the patient's blood or liver tis-
sue. The pre-S region is PCR-amplified using PCR-1R and 5'-
dig-labeled 1F primers. The PCR products are visualized using 
agarose gel electrophoresis and ethidium bromide staining. In 
cases where no PCR products are seen---perhaps because of 
a low HBV DNA titer---nested PCR using PCR-2R and 5'-dig-
labeled 1F primers is done. When only a single PCR product 
is seen, the DNA product is directly subjected to chip hybrid-
ization. However, when two or more different types of pre-S 
PCR products are seen in agarose gel, the products are first 
directed to TA cloning. Multiple plasmid clones are then ana-
lyzed using colony PCR with M13R and 5'-dig-labeled 13F 
primers. These PCR products are then analyzed using the 
Pre-S Gene Chip.
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Results
Using DNA sequencing analysis, we first detected pre-S
deletion mutations in the sera of HBV carriers and
patients with HBV-related HCC. The pre-S mutation rate
was relatively low (7%) in the sera of patients with high
HBV titers, which indicates the acute phase of HBV infec-
tion (Table 2). The pre-S deletion rate gradually increased
during periods of persistent HBV infection: the rate was
37% in HBV carriers with low serum HBV titers, which
indicated the chronic phase of HBV infection. In HCC
patients with HBV infection, the pre-S deletion rate was as
high as 60%, which suggested that pre-S mutants emerge
during long-term persistence of the HBV genome in carri-
ers, and that they facilitate the development of HCC.
To efficiently detect pre-S deletion mutations, we devel-
oped a Pre-S Gene Chip on which contained 42 DNA
probes that targeted the pre-S region of the LHBS gene
(Fig. 2). To test the efficacy of the chip, we first used iso-
lated plasmids containing wild-type HBV, pre-S1 mutant
with nt 3044 to 3103 of the LHBS gene deleted, and pre-
S2 mutant with nt 3 to 57 deleted [28]. These wild-type
and pre-S mutant LHBS genes were initially isolated from
genotype B HBV carriers in Taiwan [11,12]. The wild-type
clone hybridized to all the DNA probes on the chip (Fig.
4). The pre-S1 and -S2 mutants, however, showed signals
missing in probes 6 to 7, which spanned nt 3044 to 3103
in the pre-S1 region, and probes 12 to 13, which spanned
nt 3 to 62 in the pre-S2 region, respectively. These results
showed that the Pre-S Gene Chip correctly detected the
pre-S deletions in the LHBS gene.
We then did a blind test on 20 cases to compare the pre-S
typing results yielded by the Pre-S Gene Chip with those
provided by classic DNA sequencing. Overall, the Pre-S
Gene Chip yielded consistent pre-S deletion detection
results with DNA sequencing (Table 3). Because the Pre-S
Gene Chip used DNA hybridization signals to detect DNA
deletions, the ranges spanning the deleted regions might
have shifted a few nucleotides from the DNA sequencing
results; however, that appeared not to have affected its
identifying pre-S deletions in samples. In summary, DNA
sequencing and Pre-S Gene Chip analyses were used to
identify 21 and 19 pre-S deletion clones, respectively. The
detection rates for pre-S deletions in these HBV carriers
were 70% (14/20) for DNA sequencing and 65% (13/20)
for the Pre-S Gene Chip. These data indicated that the Pre-
S Gene Chip offered a sensitive assay compatible with
DNA sequencing. We also found that 9 of the 14 pre-S
mutant-positive cases had multiple pre-S products and
that most (8/9) simultaneously contained wild-type as
well as pre-S mutants. In addition, 4 cases had multiple
mutation clones. This finding showed that wild-type and
multiple pre-S mutant LHBS clones often co-existed in
one individual.
Discussion
In this study, we developed an oligonucleotide array sys-
tem to detect deletions in the pre-S regions of the HBV
LHBS gene in chronic carriers with detectable HBV DNA,
the group of carriers at a high risk of HCC [10]. We found
that multiple mutation clones often co-exist in a carrier,
making genotyping tedious and time-consuming. Clon-
ing individual PCR products is usually necessary to differ-
entially genotype the different pre-S deletion products.
We found that doing colony PCR of the individual gene
clones, and then directly applying the PCR products to the
Pre-S Gene Chip for hybridization and detection, was
more time- and cost-effective than traditional DNA
sequencing analysis. The Pre-S Gene Chip is made of a
0.7-cm2 nylon membrane and costs substantially less than
DNA sequencing analysis, especially for clinical institu-
tions without internal access to a DNA sequencing service.
The DNA chip system also simultaneously detects multi-
ple pre-S clones, which makes it convenient for large-scale
pre-S mutation screenings in chronic HBV carriers. Using
the Pre-S Gene Chip and DNA sequencing in blind tests of
20 cases showed that both methods had close detection
rates of pre-S deletions. Therefore, we conclude that the
Pre-S Gene Chip delivered comparable results to direct
Table 2: Pre-S mutations in patients with different serum HBV DNA titers
Status Serum HBV DNA Titer* Cases (n) HBV Clones# (n) Clones with Pre-S Deletions (n)P r e v a l e n c e
Hepatitis High 53 57 4 7.0%
Intermediate 62 72 10 13.9%
Low 43 54 20 37.0%
HCC - 43 73 44 60.3%
HCC, hepatocellular carcinoma.
*High titer: HBV genome  108 copies/mL serum; intermediate titer: HBV genome  106 and < 108 copies/mL serum; low titer: HBV genome < 106 
copies/mL serum.
#The different pre-S HBS PCR products in one case were individually cloned and sequenced.Journal of Biomedical Science 2009, 16:84 http://www.jbiomedsci.com/content/16/1/84
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DNA sequencing and is a good screening method for pre-
S deletions. A minor disadvantage of the Pre-S Gene Chip
system is that it does not appear to be sensitive enough to
detect deletions less than 10 nt long: in one blind-tested
case, the chip did not identify a 10-nt deletion clone. Nev-
ertheless, considering cost and convenience, the Pre-S
Gene Chip is potentially good for large-scale screening of
pre-S deletions; perhaps it can be improved.
In this study, we found that pre-S deletion rates were sig-
nificantly higher in the late phase of chronic HBV infec-
tion, which displays lower HBV titers, than in the acute
infection phase, which displays high viral titers. In the
HBV-induced HCC stage, the pre-S deletion rate was as
high as 60%. These findings suggested that pre-S deletions
probably occur during long-term persistent HBV infection
and eventually become predominant in HBV carriers.
Therefore, we hypothesize that pre-S mutants are impor-
tant in liver carcinogenesis. Our earlier studies [27,28]
found that pre-S mutant LHBS accumulated in ER, where
it caused ER and oxidative stress [27,28]. It also strongly
induced DNA damage and mutations, which destabilized
the genome [28]. We found that the pre-S2 mutant LHBS
induces cyclin A overexpression, cell cycle progression,
and cell proliferation, all essential factors for carcinogen-
esis [29,30]. These earlier findings showed that pre-S
mutant LHBS, especially the pre-S2 type, is involved in car-
cinogenesis. Identifying the pre-S deletion mutations in
chronic HBV carriers is therefore important when screen-
ing for persons at high risk for HCC.
In addition to pre-S deletions, a number of HBV markers,
such as HBV viral titers and HBeAg, are also believed to be
associated with the risk of HCC in chronic HBV carriers
[9,10]. HBV replication causes liver injury and inflamma-
tion, which releases cytokines and facilitates the develop-
ment of fibrosis and liver cell proliferation [7,8]. In
addition, the HBV protein HBX crosstalks with various
host factors and behaves as a viral oncoprotein [33,34]. It
transactivates a number of cellular promoters, acting on
cis-acting regulatory elements [35]. It also regulates pro-
teasome function and, thus, controls the degradation of
cellular and viral proteins [36]. We hypothesize that pre-S
mutant LHBS strengthens the detrimental effects of HBX
protein by increasing cell proliferation and genomic insta-
bility, thereby facilitating hepatocellular carcinogenesis.
Conclusion
We developed the Pre-S Gene Chip system to screen for
pre-S deletions in the LHBS gene. The detection sensitivity
of the Pre-S Gene Chip for pre-S mutations is close to that
of direct DNA sequencing analysis, but it is much more
time- and cost-effective. We believe that the Pre-S Gene
Chip is feasible for the large-scale screening of pre-S muta-
tions in chronic HBV carriers. Combining the detection of
pre-S mutations with other HBV factors, such as HBV viral
titers and HBeAg, should offer a reliable predictive
method for HCC risk in chronic HBV carriers.
Results of the Pre-S Gene Chip analysis Figure 4
Results of the Pre-S Gene Chip analysis. A: The wild-
type LHBS gene. B: The pre-S1 mutant LHBS, with nt 3044-
3103 of the HBV genome deleted. The signals on probes 6 
(nt 3045-3071) and 7 (nt 3074-3103) are negative. C: The 
pre-S2 mutant LHBS, with nt 3-57 of the HBV genome 
deleted. The signals on probes 12 (nt 3-32) and 13 (nt 33-62) 
are negative.
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